Amgen (AMGN) has confirmed the date for its third-quarter 2026 financial results, scheduled to be released on November 3 after the close of U.S. markets. The company's investor conference call is set to begin at 4:30 p.m. Eastern Time and will feature CEO Robert A. Bradway alongside other senior management members. This announcement provides investors with a specific near-term catalyst to monitor ahead of the earnings report. The event marks the next scheduled test of Amgen's operating performance, allowing the market to assess the company's ability to balance its commercial momentum with ongoing investments in its development pipeline. Amgen stock was trading at EUR 413.03 in Berlin on October 29, reflecting a 2.99% increase from the previous session's close. While the specific earnings figures are not yet available, the confirmed date adds clarity to the company's quarterly calendar following recent updates regarding its clinical pipeline and dividend timetable. The upcoming results will be critical for determining the direction of Amgen's share price, as investors will focus on management commentary and the forward-looking outlook provided during the webcast. The live event will be available to the public and archived for at least 90 days.